Download as PDF - Provectus Biopharmaceuticals

Provectus Pharmaceuticals Inc. Will Present at the
Wall Street Analyst Forum 19th Annual Analyst
Conference
Tuesday September 9, 2008
September 10, 2008 at 11:50 AM at The University Club in New York City
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT,
http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, today
announced that Chairman and CEO, Craig Dees, Ph.D., will present at The Wall Street Analyst Forum 19th
Annual Analyst Conference on Wednesday, September 10 at 11:50 a.m. Eastern time. This conference will be
held at The University Club in New York. It will also be webcast at http://wsw.com/webcast/wsaf7/pvct.ob
Craig Dees will review the results of the Phase I clinical trial Provectus has completed in melanoma patients.
In this study, individual tumors were injected with PV-10, in many cases causing them to become necrotic and
dying within 7 days, and lifting off the skin within 14 days.
Provectus is currently operating a phase 2 study, led by renowned oncology researcher Professor John F.
Thompson, M.D., Director of the Sydney Melanoma Unit at The University of Sydney. Recently, Provectus
announced that the first 20 of 80 patients in this phase 2 study have been treated with PV-10. Additional
subjects are being evaluated for eligibility into the trial or are awaiting treatment at the three active centers in
Brisbane and Sydney, Australia, and the M.D. Anderson Cancer Center, in Houston, TX. In addition,
Provectus anticipates opening further sites in the US and Australia in the coming months. Currently,
Provectus is sponsoring Phase 2 trials for its other lead drug, PH-10, for psoriasis and atopic dermatitis in
New York and Florida.
Dees stated, "We are aware that those with melanoma, their physicians, as well as the investment community,
are hungry for information regarding our progress in these clinical trials, but for sound reasons, the Food and
Drug Administration is strict about what can and cannot be divulged. We will continue to update the market
as well as our fellow oncologists and their patients to the extent we can under these parameters. We intend to
provide as much information as we are allowed at the Wall Street Analysts Forum."
According to the American Cancer Society, more than 62,000 people are expected to be diagnosed in the in
the US in 2008 with melanoma, the most serious form of skin cancer, leading over 8,000 deaths this year.
About The Wall Street Analyst Forum
The Wall Street Analyst Forum sponsors annual investor conferences that provide a forum for participating
publicly traded mid- and small-cap companies to meet with buy/sell side analysts and portfolio managers from
money management firms. For more information visit http://www.analyst-conference.com
About Provectus Pharmaceuticals, Inc. (www.pvct.com)
1/2
Provectus Pharmaceuticals is a development stage biopharmaceutical company that specializes in oncology
and dermatology therapies that are safer, more effective, less invasive and more economical than conventional
therapies. Provectus is currently conducting phase 2 clinical trials of their proprietary drugs PV-10 as a
therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis.
Information about these and the Company's other clinical trials can be found at the NIH registry,
www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma
indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual
properties and technologies in the areas of imaging, medical devices and biotechnology. For additional
information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay &
Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to
certain risks and uncertainties that could cause actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking
statements, which reflect management's analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise
after the date thereof.
Contact:
Provectus Pharmaceuticals, Inc.
Peter R. Culpepper, CFO, 866-594-5999 #30
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, VP - Investor Relations
Bill Gordon, SVP - Media Relations
212-564-4700
Source: Provectus Pharmaceuticals, Inc.
2/2